Chromis Therapeutics Inc., an antiviral drug discovery company in San Diego, has raised $3 million in a seed financing round led by Torrey Pines Investment.

Chromis will use the funds to advance its platform of antiviral drugs, including a treatment for the hepatitis B virus (HBV).

It’s estimated that 400 million people suffer from chronic HBV infection, according to the Hepatitus B Foundation. The infection is also a leading cause of cancer-related morbidity and mortality worldwide.

“Current available antiviral options suppress viral replication and improve patient survival but they do not eradicate the virus,” said Nikolay Savchuk, managing partner at Torrey Pines Investment, in a statement. “This is why Chromis' antiviral drugs have such a significant potential, they aim at not only treating, but eradicating the HBV virus."